Medifoxamine
Clinical data | |
---|---|
Trade names | Clédial, Gerdaxyl |
Other names | Medifoxamine fumarate; N,N-Dimethyl-2,2-diphenoxyethylamine |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 21%[1][2] |
Elimination half-life | 2.8 hours (acute);[1][2] 4.0 hours (chronic)[3] |
Identifiers | |
| |
JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Medifoxamine, previously sold under the brand names Clédial and Gerdaxyl, is an
withdrawn from the market in 1999 (Morocco) and 2000 (France) following incidences of hepatotoxicity.[10][12][13]
Pharmacology
Pharmacodynamics
Medifoxamine has been found to act preferentially as a relatively weak
serotonin receptors including 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT3 (>10,000 nM).[3] As medifoxamine is metabolized extensively in the liver during first-pass metabolism, and as these metabolites have as much as 3-fold greater activity relative to medifoxamine, it is likely that they contribute significantly to the pharmacology of the parent drug.[3]
Effectiveness and tolerability
Unlike many
controlled clinical studies have found it to have similar effectiveness to imipramine, clomipramine, and maprotiline in the treatment of depression.[3][9][18][19]
Society and culture
Generic names
Medifoxamine is the
while médifoxamine is itsBrand names
Medifoxamine was marketed under the brand names Clédial and Gerdaxyl.[6][7]
References
- ^ PMID 2291875.
- ^ ISBN 978-3-527-64565-7.
- ^ S2CID 6978939.
- ISBN 978-1-118-28181-9.
- ISBN 978-0-08-058366-2.
- ^ ISBN 978-1-4757-2085-3.
- ^ ISBN 978-3-88763-075-1.
- ^ ISBN 978-0-7514-0499-9.
- ^ PMID 8668756.
- ^ ISBN 978-92-1-130230-1.
- PMID 2380545.
- PMID 12506267.
- ISBN 978-981-4287-59-3.
- ^ PMID 1389953.
- S2CID 54309929.
- S2CID 41078092.
- PMID 7988407.
- ^ PMID 8275921.
- ^ S2CID 145601579.
- ISBN 978-0-08-058364-8.